Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO 2012 Lung Cancer Highlights: Dr. Socinski on Continuation Maintenance Alimta in PARAMOUNT Trial
Dr West
Author
Howard (Jack) West, MD

The first of several podcasts we'll be adding here from our ASCO 2012 Lung Cancer Highlights program, co-sponsored with LUNGevity Foundation, is with Dr. Mark Socinski, Professor at the University of Pittsburgh, who discussed the updated results of continuation maintenance therapy with Alimta (pemetrexed) on the PARAMOUNT trial.  Here is his summary of the presentation that now includes data on the overall survival in that study, which demonstrated a significant benefit for the recipients of continuation maintenance Alimta.

Dr. Socinski ASCO LC Highlights PARAMOUNT Trial Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Transcript

Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Figs

We'll turn out the podcasts from this program in rapid succession. Look for the next one, with Dr. Socinski reviewing an important trial on poor performance status patients with advanced NSCLC, very soon.

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi app.92,  Welcome to Grace.  I'm sorry this is late getting to you. And more sorry your mum is going through this.  It's possible this isn't a pancoast tumor even though...

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Recent Comments

JOIN THE CONVERSATION
Hi app.92,  Welcome to Grace…
By JanineT GRACE … on
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on